Federation Des Caisses Desjardins Du Quebec Madrigal Pharmaceuticals, Inc. Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 Aug 30, 2024	SELL	$66.76 - $93.49 $10,014 - $14,023	-150 Closed	0 $0
Q4 2019 Aug 30, 2024	BUY	$84.28 - $118.5 $12,642 - $17,775	150 New	150 $13.7 Million
Q2 2019 Aug 30, 2024	SELL	$91.13 - $142.5 $2,825 - $4,417	-31 Closed	0 $0
Q4 2018 Aug 30, 2024	BUY	$94.77 - $215.54 $2,937 - $6,681	31 New	31 $3.49 Million
Q2 2017 Aug 30, 2024	BUY	N/A	31	31 $504,000

Others Institutions Holding MDGL

# of Institutions

298

Shares Held

22M

Call Options Held

819K

Put Options Held

640K

Janus Henderson Group PLC London, X0

2.48M
Shares

$775 Million
0.28% of portfolio
John Paulson Paulson & Co. Inc. | New York, Ny

2.04M
Shares

$639 Million
29.57% of portfolio
Avoro Capital Advisors LLC New York, NY

2.03M
Shares

$635 Million
6.48% of portfolio
Rtw Investments, LP New York, NY

1.99M
Shares

$624 Million
6.74% of portfolio
Baker Bros. Advisors LP New York, NY

1.97M
Shares

$618 Million
4.49% of portfolio

View Full List

About MADRIGAL PHARMACEUTICALS, INC.

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.35B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

More about MDGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account